PROM1 and central nervous system cancer: Collectively, our results provide a unifying explanation for existing controversies regarding the association between the tumorigenic potential of glioma cells and CD133+ phenotype and more generally, the potential significance of CD133/AC133 as a predictive biomarker and prognostic indicator of clinical outcome in patients with GBM.